Head of Strategy & Corporate Development at Illumina

San Diego, California, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Genomics, HealthcareIndustries

Requirements

Experienced and strategic leader with deep experience leading strategy, transformation, and integration in complex, global life sciences organizations
Ability to partner closely with C-suite, Head of M&A, and Business Unit General Managers
Expertise in corporate strategic planning, including integrating market trends, technology roadmaps, competitive dynamics, and long-range enterprise strategy
Proficiency in partnering with Strategic Finance for setting priorities, portfolio trade-offs, and capital allocation
Skills in providing structured, forward-looking views of emerging growth vectors (e.g., emerging applications, adjacent markets, technology and data innovations) and aligning deal pipelines
Capability to deliver strategic insights and portfolio recommendations to CEO, executive leadership team, and Board of Directors
Experience in business unit strategic planning, including shaping three-year growth strategies, market segmentation, competitive positioning, and source-of-advantage analysis
Ability to apply standardized frameworks for assessing market attractiveness, share position, and investment priorities
Proficiency in translating strategies into quantified outcomes (revenue, EBIT, FCF, capital requirements) and driving enterprise alignment/portfolio trade-offs
Oversight experience for global organizations connecting strategy to execution, including transformation agendas and post-merger integration

Responsibilities

Lead Illumina’s enterprise strategic planning process, integrating market trends, technology roadmaps, and competitive dynamics into long-range strategy
Partner with Strategic Finance to set enterprise priorities, manage portfolio trade-offs, and guide capital allocation toward highest-value opportunities
Provide forward-looking view of emerging growth vectors and collaborate with VP of M&A to align deal pipeline with strategic priorities
Deliver strategic insights and portfolio recommendations to CEO, executive leadership team, and Board of Directors
Partner with BU GMs to shape three-year growth strategies for Clinical, Multi-Omics, BioInsights, Core, Arrays, and Services
Define "where to play and how to win" through market segmentation, competitive positioning, and source-of-advantage analysis
Translate BU strategies into quantified outcomes (revenue, EBIT, FCF, capital requirements) and drive enterprise alignment/portfolio trade-offs
Connect BU initiatives to transformation vehicles, monitor progress against milestones, and strengthen BU strategy capabilities
Lead and scale enterprise transformation agenda (SEO/SPO), delivering P&L impact through revenue growth, cost optimization, and operating-model redesign
Oversee post-merger integration (IMO) to ensure operational, cultural, and strategic alignment with acquired businesses

Skills

Strategic Planning

Corporate Development

M&A

Business Transformation

Capital Allocation

Portfolio Management

Revenue Growth

Cost Optimization

Operating Model Design

Post-Merger Integration

P&L Management

Illumina

Supports genomics startups through funding and resources

About Illumina

Illumina focuses on fostering innovation in the genomics industry by supporting startups through its Illumina Accelerator program. This program helps entrepreneurs create, launch, and grow genomics-focused companies by providing funding and resources. The accelerator operates in two main locations: the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator has successfully invested in 68 genomics startups, which have collectively raised over $1 billion in venture capital. What sets Illumina apart from its competitors is its strong partnership with leading venture capital investors and its dedicated focus on the genomics sector. The goal of Illumina is to build a thriving ecosystem for genomics innovation, enabling new companies to emerge and advance the field.

San Diego, CaliforniaHeadquarters

1998Year Founded

$27.2MTotal Funding

IPOCompany Stage

Venture Capital, BiotechnologyIndustries

5,001-10,000Employees

Risks

Over-reliance on NVIDIA's AI technology may limit flexibility in AI solution adoption.

Standardizing proteomics data across platforms could challenge Illumina's data reliability.

Single-flow-cell NovaSeq X System might cannibalize sales of higher-end models.

Differentiation

Illumina leads in genomic sequencing with advanced AI integration and multiomic data analysis.

The company offers innovative array-based solutions for DNA, RNA, and protein analysis.

Illumina's global expansion includes a new Global Capability Center in Bengaluru.

Upsides

Collaboration with NVIDIA enhances drug discovery and clinical development through AI integration.

Pilot proteomics program with UK Biobank aims to generate crucial reference datasets.

Single-cell sequencing kits make high-throughput sequencing accessible to smaller labs.

Land your dream remote job 3x faster with AI

Try Jobo Free